Mylan to buy injectable drugs unit of India's Strides Arcolab Ltd for $1.6 bn

Feb 28 2013, 08:17 IST
Comments 0
The increased portfolio is also likely to help Mylan as many generic injectable drugs. (Reuters) The increased portfolio is also likely to help Mylan as many generic injectable drugs. (Reuters)
SummaryThe increased portfolio is also likely to help Mylan as many generic injectable drugs.

earlier. Excluding items, the company reported 65 cents per share.

Total revenue rose 12 percent to $1.72 billion.

Analysts had expected a profit of 64 cents per share on revenue of $1.73 billion, according to Thomson Reuters I/B/E/S.

The company forecast 2013 earnings $2.75 to $2.95 per share on revenue of $7 billion to $7.4 billion. Analysts were expecting earnings of $2.80 per share on revenue of $7.16 billion.

Single Page Format
Ads by Google
Reader´s Comments
| Post a Comment
Please Wait while comments are loading...